MINDY1 and hepatocellular carcinoma: Combining the above-mentioned studies, it was confirmed that MINDY1 promoted PD-L1 deubiquitination by stimulating the Wnt/β-catenin pathway, inhibited CD8+ T cells activation, and further promoted HCC immune escape.